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ABSTRACT 
Objective: Gastro-oesophageal reflux is a public health concern which could have associated 
oesophageal complications, including adenocarcinoma, and possibly also head-and-neck and 
lung cancer. The aim of this study was to test the hypothesis that reflux increases all-cause 
and cancer-specific mortality in an unselected cohort. 
Design: The Nord-Trøndelag health study (HUNT), a Norwegian population-based cohort 
study, was used to identify individuals with and without reflux in 1995-1997 and 2006-2008, 
with follow-up until 2014. All-cause and cancer-specific mortality were assessed from the 
Norwegian Causes of Death Registry and Cancer Registry. Multivariable Cox-regression was 
used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for mortality with 
adjustments for potential confounders. 
Results: We included 4,758 participants with severe reflux symptoms and 51,381 
participants without reflux symptoms, contributing 60,323 and 747,239 person-years at risk, 
respectively. Severe reflux was not associated with all-cause mortality, overall cancer-
specific mortality, or mortality in cancer of the head-and-neck or lung. However, for men 
with severe reflux a 6-fold increase in oesophageal adenocarcinoma-specific mortality was 
found (HR 6.09, 95% CI 2.33 to 15.93) and the mortality rate was 0.27 per 1000 person-
years.  For women, the corresponding mortality was not significantly increased (HR 3.68, 
95% CI 0.88 to 15.27) and the mortality rate was 0.05 per 1000 person-years.  
Conclusion: Individuals with severe reflux symptoms do not seem to have increased all-
cause mortality or overall cancer-specific mortality. Although the absolute risk is small, 
individuals with severe reflux symptoms have a clearly increased oesophageal 
adenocarcinoma-specific mortality.
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What is already known about this subject? 
 Gastro-oesophageal reflux disease is defined by troublesome symptoms of heartburn 
or regurgitation 
 Gastro-oesophageal reflux disease is frequent in Western populations and the 
prevalence is increasing 
 Gastro-oesophageal reflux disease is associated with several complications, including 
oesophageal adenocarcinoma and possibly cancers of the head-and-neck and lung. 
What are the new findings? 
 Severe reflux symptoms were not associated with any increased all-cause mortality, 
overall cancer-specific mortality, or head-and-neck and lung cancer-specific mortality 
 Severe reflux symptoms were associated with increased oesophageal 
adenocarcinoma-specific mortality 
 As only 14 of 4,758 individuals with severe reflux symptoms were diagnosed with 
oesophageal adenocarcinoma, the absolute risk is low 
How might it impact on clinical practice in the foreseeable future? 
 Gastro-oesophageal reflux disease can be considered a benign disorder with no 
increased all-cause mortality. However, the clinician should be aware of the clear 
association with oesophageal adenocarcinoma and oesophageal adenocarcinoma-
specific mortality, and rapid endoscopy should be performed if suspected
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INTRODUCTION 
Gastro-oesophageal reflux disease (GORD) is a public health concern that affects as many as 
10-30% of the adult population in Western countries and the prevalence is increasing 1 2. The 
main established risk factors for GORD are heredity, obesity, and tobacco smoking 3-5. GORD 
is defined by troublesome symptoms of heartburn or regurgitation, and is associated with 
substantial reductions in health-related quality of life and coincides with several other 
conditions, including  sleep problems, asthma and other respiratory disorders 6-9. 
Complications of GORD include oesophagitis, peptic strictures of the oesophagus, Barrett’s 
oesophagus, and oesophageal and oesophagogastric junctional adenocarcinomas 10 11. 
Oesophageal and junctional adenocarcinomas are characterized by poor prognosis with a 5-
year survival below 20%, increasing incidence, and a male predominance 12-14. GORD is also 
associated with some extra-oesophageal cancers, including head-and-neck and lung cancer 
15-17. Despite the fact that GORD is associated with all these conditions, few studies have 
examined whether GORD is associated with a reduced overall prognosis or increased risk of 
cancer-specific mortality. The results from the available literature are conflicting 18-20. 
As the risk of oesophageal adenocarcinoma is known to be increased in reflux, we expected 
to find increased mortality from oesophageal adenocarcinoma and, thereby, also increased 
overall cancer-specific and all-cause mortality.  Due to the association with head-and-neck 
and lung cancer, we also expected to find increased mortality from these cancers. The aim of 
this study was to test these hypotheses in a large and unselected cohort of individuals.
6 
 
METHODS 
Design 
For the purpose of this study, data from the Norwegian population-based cohort study, the 
Nord-Trøndelag health study (HUNT), was used. All residents of Nord-Trøndelag county aged 
20 years and older were invited to participate in three consecutive health surveys: HUNT1 
(January 1, 1984 to February 28, 1986), HUNT2 (August 1, 1995 to June 30, 1997) and HUNT3 
(October 1, 2006 to June 30, 2008). In addition, a separate questionnaire was sent to non-
participants after HUNT3 in 2009 (questionnaire for nonparticipants). HUNT includes 
questionnaires that cover a wide range of health-related information, including reflux 
symptoms, lifestyle factors, and clinical measurements. Data on reflux symptoms were 
available in HUNT2, HUNT3, and the questionnaire for nonparticipants. Further information 
on data collection and design is available elsewhere 21. Follow-up started from the initiation 
of HUNT2 (August 1, 1995) until the end of the study (December 31, 2014), thus defining the 
study period. If an individual participated in both HUNT2 and HUNT3 or the questionnaire 
for nonparticipants, follow-up started at date of participation in HUNT2.  
Follow-up involved linking the HUNT data to the Norwegian Cancer Registry and the 
Norwegian Cause of Death Registry, using the 11-digit national identity number assigned to 
each Norwegian resident. All deaths in Norway are registered in the Norwegian Cause of 
Death Registry and the Cancer Registry of Norway has a high level of completeness (98.8% in 
2001-2005) 22 23. In addition, HUNT receives updated information on emigration from 
Statistics Norway every quarter. Participants diagnosed with any cancer before participation 
in HUNT were excluded. 
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Exposure 
The study exposure was severe reflux symptoms. In HUNT2, HUNT3, and the questionnaire 
for nonparticipants the participants were asked “to what degree have you had heartburn or 
acid regurgitation in the last 12 months?” and answered according to three alternatives: 
“no”, “minor” or “severe” complaints. Participants reporting severe complaints were defined 
as exposed, and those reporting no complaints as unexposed. This definition of severe reflux 
has been validated with excellent results in a previous study, showing that 95% of 
participants reporting severe reflux symptoms experience reflux symptoms at least once a 
week 24. Those reporting minor complaints were not included in this study. Individuals 
participating in both HUNT2 and HUNT3 or the questionnaire for nonparticipants, and 
reporting different degrees of reflux symptoms (severe and never) in the different studies 
were excluded in order to avoid interchange in the exposure.  
 
Outcomes 
The study outcomes were all-cause mortality, overall cancer-specific mortality, oesophageal 
adenocarcinoma-specific mortality, and mortality from head-and-neck or lung cancer. 
All-cause mortality 
From the Cause of Death Registry, information was gathered on the dates of death among 
the participants. All deaths among the HUNT participants, i.e. independent of cause, were 
included in the calculations for all-cause mortality. 
Overall cancer-specific mortality 
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From the Cancer Registry, information was gathered on the site of cancer based on the 
International Classification of Diseases (ICD)-7 codes, morphology based on ICD-O-3 codes, 
and date of cancer diagnoses. We defined cancer deaths as deaths reported in the Cause of 
Death Registry as caused by cancer only for participants who had a cancer diagnosis 
registered in the Cancer Registry as well. Participants diagnosed with any cancer as the cause 
of death were included in the calculations for cancer-specific mortality.  
Oesophageal adenocarcinoma-specific mortality 
Participants with oesophageal adenocarcinoma as the cause of death reported in the Cause 
of Death Registry, or deaths occurring within one year from the cancer diagnosis in the 
Cancer Registry, regardless of the registered cause of death in the Cause of Death Registry, 
were included in the calculations for oesophageal adenocarcinoma-specific mortality. We 
also included oesophagogastric junctional adenocarcinomas in this outcome. 
Mortality from selected extra-oesophageal cancer sites 
The extra-oesophageal cancer sites included cancers of the head-and-neck (labial, lingual, 
salivary, oral, pharyngeal, nasosinusoidal, laryngeal cancer) and lung. Participants with any of 
these selected extra-oesophageal cancers as the cause of death reported in the Cause of 
Death Registry, or deaths occurring within one year of the cancer diagnoses in the Cancer 
Registry, regardless of registered cause of death in the Cause of Death Registry, were 
included in the calculations of extra-oesophageal cancer-specific mortality. 
Confounders 
As potential confounders we selected age, body mass index (BMI), tobacco smoking, alcohol 
consumption, physical activity, education level, chronic obstructive pulmonary disease, 
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cardiovascular diseases, diabetes, and hypertension. Information on these factors was 
collected through both HUNT2 and HUNT3. Height and weight were objectively measured by 
trained personnel in HUNT2 and HUNT3 21. In the questionnaire for non-participants, height 
and weight were self-reported. BMI was calculated by dividing weight in kilograms by height 
in meters squared (kg/m2) and categorized according to the World Health Organization’s 
classification: <18.5 (underweight), 18.5 to 25 (normal weight), 25 to 30 (overweight), or >30 
(obese) 25. The participant’s tobacco smoking status was categorized as never, previous, or 
current. Alcohol consumption was assessed by the number of occasions of consumption per 
month and categorized as less than weekly or at least weekly or consumption. Physical 
activity was assessed by hours or occasions of physical activity per week. High physical 
activity was defined as at least one hour, or at least one occasion, of physical activity per 
week. In addition, participants who reported high levels of walking at work were categorized 
into the high physical activity group. Low physical activity was anything lower than these cut-
offs for high activity. Educational level was categorized as 12 years and less or more than 12 
years of formal education. The presence of comorbidities was based on self-reported 
questionnaires. Chronic obstructive pulmonary disease included chronic bronchitis, 
emphysema, and cough with phlegm for periods of at least 3 months. In addition, 
participants reporting previous or current asthma who also reported previous or current 
smoking were defined as having chronic obstructive pulmonary disease. Cardiovascular 
disease included previous myocardial infarction, angina pectoris, or stroke/brain 
haemorrhage. The presence of diabetes was reported by the participants. Those participants 
reporting previous or current use of medication for high blood pressure were defined as 
having hypertension. 
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Statistical analysis 
Time at risk was defined from the date of the first participation in HUNT2, HUNT3, or the 
questionnaire for nonparticipants until date of death, emigration, or the end of the study 
(December 31, 2014), whichever came first. Hazard ratios (HRs) with 95% confidence 
intervals (CIs) were calculated using multivariable Cox-regression comparing the mortality 
among individuals reporting severe reflux symptoms with those reporting no reflux 
symptoms. All analyses were performed separate for each sex. The HRs were adjusted for 
age (continuous variable), BMI (<18.5, 18.5 to 25, 25 to 30, or >30), tobacco smoking status 
(never, previously, or current), alcohol consumption (<weekly or ≥weekly), physical activity 
(high or low), education (≤12 years or >12 years), chronic obstructive pulmonary disease (yes 
or no), cardiovascular diseases (yes or no), diabetes (yes or no), and hypertension (yes or 
no). In addition, analyses were stratified by age (<40, 40 to 60, and >60 years) to evaluate 
effect modification. 
 
Ethical approval 
The study has ethical approval through the Regional Committee for Medical and Health 
Research Ethics, Central Norway (2012/1290 4.2009.328), including additional approval of 
the present study (approved 02.11.2015). All participants in HUNT gave written informed 
consent when participating stating that their data could be used in future medical research, 
including linkage to other registries.
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RESULTS 
Study participants 
A flowchart showing all exclusions of individuals considered for participation is shown in the 
Figure. After exclusion of 750 individuals (1.3%) due to different degree of reflux symptoms 
reported in the different studies, 4,758 individuals with severe reflux symptoms and 51,381 
without reflux symptoms participated, contributing 60,323 and 747,239 person-years at risk, 
respectively. The average follow-up was 14.4 years. Baseline characteristics of the study 
participants are shown in Table 1. The participants with reflux were older, had higher BMI, 
drank alcohol less frequently, were more physically active, less educated, and had more 
comorbidity than those without reflux, while the groups had a more similar distribution of 
sex and tobacco smoking status (Table 1). In total 9,093 deaths occurred in the study 
population. The number of deaths for each sex, outcome, and reflux status is shown in Table 
2.  
Table 1. Baseline characteristics of the study participants 
    
  
Severe reflux No reflux 
  
Number (%) Number (%) 
Total 
  
4,758 (100.0) 51,381 (100.0) 
Age 
 
Median years (range) 51.9 (19.3 to 101.1) 44.7 (19.1 to 102.1) 
Sex 
 
Men 2,301 (48.4) 23,699 (46.1) 
 
Women 2,457 (51.6) 27,682 (53.9) 
Body mass index 
 
<18.5 14 (0.3) 454 (0.1) 
 
18.5 to 25 998 (21.0) 22,761 (44.3) 
 
25 to 30 2,245 (47.2) 20,558 (40.0) 
 
>30 1,453 (30.5) 7,052 (13.7) 
 
Missing 48 (1.0) 556 (1.1) 
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Tobacco smoking status 
 
Never 1,579 (33.2) 23,725 (46.2) 
 
Previous 1,648 (34.6) 12,861 (25.0) 
 
Current 1,447 (30.4) 14,027 (27.3) 
 
Missing 84 (1.8) 768 (1.5) 
Alcohol consumption 
 
<Weekly 2,944 (61.9) 29,423 (57.3) 
 
≥Weekly 1,814 (38.1) 21,958 (42.7) 
Physical Activity 
 
High 2,381 (50.0) 23,017 (44.8) 
 
Low 2,123 (44.6) 26,532 (51.6) 
 
Missing 254 (5.3) 1832 (3.6) 
Education 
 
≤12 years 3,297 (69.3) 31,640 (61.6) 
 
>12 years 479 (10.1) 9,563 (18.6) 
 
Missing 982 (20.6) 10,178 (19.8) 
Chronic obstructive pulmonary disease 
 
Yes 270 (5.7) 966 (1.9) 
 
No 4,380 (92.1) 48,504 (94.4) 
 
Missing 108 (2.3) 1,911 (3.7) 
Cardiovascular disease 
 
Yes 547 (11.5) 2,950 (5.7) 
 
No 4,150 (87.2) 46,685 (90.9) 
 
Missing 61 (1.3) 1,746 (3.4) 
Diabetes 
 
Yes 193 (4.1) 1,450 (2.8) 
 
No 4,547 (95.6) 49,806 (96.9) 
 
Missing 18 (0.4) 125 (0.2) 
Hypertension 
 
Yes 1,030 (21.6) 5,971 (11.6) 
 
No 3,668 (77.1) 43,659 (85.0) 
  Missing 60 (1.3) 1,751 (3.4) 
 
Reflux and all-cause mortality 
The crude all-cause mortality was higher in women with reflux (HR 1.61, 95% CI 1.46 to 
1.78), but no difference remained after adjustment for the selected confounders (HR 1.05, 
95% CI 0.92 to 1.19) (Table 2). Age was the main factor explaining the difference in the crude 
and adjusted mortality rates in women.
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Table 2. Number of deaths, mortality rates and hazard ratios with 95% confidence intervals (CI) for all-cause, cancer-specific, oesophageal adenocarcinoma-specific, and head-
and-neck and lung cancer-specific mortality among participants reporting severe and no reflux symptoms, stratified by sex 
    
Number of 
 
Mortality rates 
 
Mortality rate ratio 
 
Hazard ratio 
Sex 
 
Outcome 
 
deaths 
 
(per 1000 person-years) 
 
(95% CI) 
 
(95% CI) 
    
Severe No 
 
Severe No 
      
    
reflux reflux 
 
reflux reflux 
   
Crude Age adjusted Fully adjusted* 
Men 
 
All-cause 
            
  
mortality 
 
397 4459 
 
13.55 13.06 
 
1.04 (0.93  to 1.15) 
 
1.07 (0.99 to 1.19) 0.97 (0.87 to 1.07) 0.95 (0.84 to 1.07) 
  
Overall cancer- 
            
  
specific mortality 
 
108 1200 
 
3.68 3.51 
 
1.05 (0.85 to 1.28) 
 
1.09 (0.89 to 1.32) 0.99 (0.81 to 1.21) 1.08 (0.87 to 1.34) 
  
Oesophageal 
            
  
adenocarcinoma- 
            
  
specific mortality 
 
8 17 
 
0.27 0.05 
 
5.48 (2.05 to 13.4) 
 
5.45 (2.35 to 12.66) 4.89 (2.10 to 11.39) 6.09 (2.33 to 15.93) 
  
Head-and-neck and 
            
  
lung cancer- 
            
  
specific mortality 
 
31 303 
 
1.06 0.89 
 
1.19 (0.80 to 1.73) 
 
1.24 (0.85 to 1.79) 1.13 (0.78 to 1.64) 1.09 (0.71 to 1.67) 
               Women 
 
All-cause 
            
  
mortality 
 
430 3807 
 
13.86 9.38 
 
1.48 (1.33 to 1.63) 
 
1.61 (1.46 to 1.78) 1.05 (0.95 to 1.16) 1.05 (0.92 to 1.19) 
  
Overall cancer- 
            
  
specific mortality 
 
98 943 
 
3.16 2.32 
 
1.36 (1.09 to 1.68) 
 
1.49 (1.21 to 1.83) 1.07 (0.87 to 1.32) 1.11 (0.87 to 1.42) 
  
Oesophageal 
            
  
adenocarcinoma- 
            
  
specific mortality 
 
4 10 
 
0.13 0.02 
 
5.23 (1.20 to 18.14) 
 
5.67 (1.78 to 18.10) 3.92 (1.22 to 12.61) 3.68 (0.88 to 15.27) 
  
Head-and-neck and 
            
  
lung cancer- 
                specific mortality 
 
17 189 
 
0.55 0.47 
 
1.18 (0.67 to 1.93) 
 
1.29 (0.78 to 2.11) 0.96 (0.59 to 1.59) 1.21 (0.68 to 2.16) 
*Adjusted for age, body mass index, tobacco smoking, alcohol consumption, physical activity, education, chronic obstructive pulmonary disease, cardiovascular diseases, 
diabetes, and hypertension 
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Reflux and overall cancer-specific mortality 
The crude cancer-specific mortality of all cancer types was increased in women with reflux 
(HR 1.49, 95% CI 1.21 to 1.83), but after adjustment for age and other confounders this 
increase became attenuated and statistically non-significant (HR 1.11, 95% CI 0.87 to 1.42) 
(Table 2). 
 
Reflux and oesophageal adenocarcinoma-specific mortality 
The oesophageal adenocarcinoma-specific mortality was higher among men with reflux than 
those without. A 6-fold difference remained after adjustment for confounders (HR 6.09, 95% 
CI 2.33 to 15.93). For women with reflux, the crude oesophageal adenocarcinoma-specific 
mortality was increased (HR 5.67, 95% CI 1.78 to 18.10), but after adjustments the 
association attenuated and became statistically non-significant (HR 3.68, 95% CI 0.88 to 
15.27) (Table 2). No participants with severe reflux symptoms died of oesophageal 
squamous cell carcinoma, compared to 17 participants without reflux symptoms.  
 
Reflux and mortality from head-and-neck and lung cancer 
The head-and-neck and lung cancer-specific mortality was not associated with reflux (Table 
2). 
 
Reflux and mortality stratified by age 
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Stratification by age categories did not substantially alter the overall results regarding all-
cause mortality or mortality related to cancer in men. In women, reflux became associated 
with increased risk of oesophageal adenocarcinoma-specific mortality among the 
participants above 60 years of age (HR 10.49, 95% CI 1.99 to 55.27) (Table 3).
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Table 3. Hazard ratios with 95% confidence intervals (CI) for all-cause mortality, overall cancer-specific mortality, oesophageal adenocarcinoma-specific mortality, and 
head-and-neck and lung cancer-specific mortality, stratified by sex and age categories 
Sex 
 
Outcome 
 
<40 years   40-60 years   >60 years 
    
Number of 
 
Hazard ratio 
 
Number of 
 
Hazard ratio 
 
Number of 
 
Hazard ratio 
    
deaths 
 
(CI 95%)* 
 
deaths 
 
(CI 95%)* 
 
deaths 
 
(CI 95%)* 
    
Severe No 
   
Severe No 
   
Severe No 
  
    
reflux reflux 
   
reflux reflux 
   
reflux reflux 
  Men 
 
All-cause 
               
  
mortality 
 
7 118 
 
0.95 (0.43 to 2.09) 
 
96 778 
 
1.02 (0.81 to 1.29) 
 
294 3563 
 
0.86 (0.74 to 0.99) 
  
Overall cancer- 
               
  
specific mortality 
 
2 28 
 
1.08 (0.24 to 4.81) 
 
35 314 
 
1.09 (0.76 to 1.58) 
 
71 858 
 
1.02 (0.77 to 1.34) 
  
Oesophageal 
               
  
adenocarcinoma- 
               
  
specific mortality 
 
0 0 
 
- 
 
4 3 
 
81.73 (8.50 to 785.53) 
 
4 14 
 
3.59 (0.98 to 13.20) 
  
Head-and-neck 
               
  
and lung cancer- 
               
  
specific mortality 
 
0 4 
 
- 
 
11 98 
 
0.81 (0.40 to 1.64) 
 
20 201 
 
1.27 (0.74 to 2.18) 
                  Women 
 
All-cause  
               
  
mortality 
 
5 96 
 
1.36 (0.54 to 3.45) 
 
52 589 
 
1.02 (0.74 to 1.40) 
 
373 3122 
 
0.93 (0.81 to 1.07) 
  
Overall cancer- 
               
  
specific mortality 
 
1 52 
 
0.55 (0.07 to 4.04) 
 
22 326 
 
0.77 (0.48 to 1.24) 
 
75 565 
 
1.24 (0.92 to 1.66) 
  
Oesophageal 
               
  
adenocarcinoma- 
               
  
specific mortality 
 
0 0 
 
- 
 
0 4 
 
- 
 
4 6 
 
10.49 (1.99 to 55.27) 
  
Head-and-neck 
               
  
and lung cancer- 
                   specific mortality   0 5   -   5 84   0.80 (0.32 to 2.01)   12 100   1.32 (0.63 to 2.77) 
17 
 
*Adjusted for body mass index, tobacco smoking, alcohol consumption, physical activity, education, chronic obstructive pulmonary disease, cardiovascular diseases, 
diabetes, and hypertension 
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DISCUSSION 
In this study severe reflux symptoms were not associated with any increase in all-cause 
mortality, overall cancer-specific mortality, or head-and-neck and lung cancer-specific 
mortality, but only an increase in oesophageal adenocarcinoma-specific mortality. 
Strengths of this study include its prospective and population-based design, which 
counteracts recall bias and selection bias. The population of Nord-Trøndelag County is 
representative of the Norwegian population as a whole 26, and therefore the results can be 
generalized to other Western populations. The data on reflux have been well validated 
against a more comprehensive assessment with excellent results 24. Cancer deaths were 
retrieved both from the Cancer Registry and the Cause of Death Registry in order to validate 
these data. The population studied was large and the time of follow-up was long, providing a 
robust statistical power. 
Limitations include possible information bias, as most of the confounders adjusted for in this 
study came from self-reported questionnaires 27 28.  
In this study we excluded the individuals reporting minor reflux symptoms. We believe these 
individuals are a heterogeneous group, most without true reflux disease. This statement is 
based on two validation studies performed on the questionnaire used in the HUNT study. In 
these validation studies, we found that 95% to 98% of the participants reporting severe 
reflux symptoms also reported at least weekly reflux symptoms, while only 25% to 31% of 
the participants reporting minor reflux symptoms also reported at least weekly reflux 
symptoms 1 24. At least weekly reflux is considered the cut-off level for defining reflux disease 
according to the Montreal definition29. We believe the group of individuals reporting minor 
reflux symptoms mostly include individuals with physiological reflux or functional complaints 
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and not individuals with true reflux disease. Thus, by excluding these, we are confident that 
the validity of the study is increased.  
In the analyses, we dichotomized three of the co-variables with large number of categories 
in the questionnaires, i.e. alcohol consumption, physical activity, and education, using 
common and previously used cut-off levels decided beforehand. This was done to maintain 
statistical power and to make the variables correspond well due to slight revisions of the 
questionnaires between the studies. We also did a sensitivity analyses with more categories 
of the co-variables in the model, and the results remained virtually unchanged (data not 
shown).  
The study has low rates of missing values among the participants (<5%), except for education 
(20%). As education was assessed in HUNT2 only, we have missing information on education 
among those participants only participating in HUNT3 or the questionnaire for 
nonparticipants. In Cox regression analyses only “complete cases” are analysed and 
participants with missing information are excluded. To assess the effect of missing data on 
education, we ran a sensitivity analysis using data from HUNT2 participants only. In this 
analysis, missing for education was reduced to only 3.6%. However, the sensitivity analysis 
did not change the results (data not shown), meaning that the missing values did not affect 
the conclusion of the study.  
The number of individuals (n=750) excluded from the analyses due to change in reported 
complaints with reflux disease between HUNT2 and HUNT3 or the questionnaire for 
nonparticipants was small number (1.3%) compared to the total number of included 
participants (n=56,139) and should not have major influence on the results.  
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As mortality was the main outcome of this study, we excluded participants with a cancer 
diagnosis in the Cancer Registry, but without this cancer reported as the cause of death in 
the Cause of Death Registry. However, for oesophageal adenocarcinoma and head-and-neck 
and lung cancers we did still include these participants if they died within one year after the 
date of cancer diagnosis, as we believe these deaths still could be related to these cancers as 
they are known to have a poor prognosis. This decision could overestimate the cancer-
specific mortality of the respective cancers, but still reflux was not associated with head-and-
neck and lung cancers-specific mortality. 
The results of this study align with those from a smaller population-based cohort study from 
the US, which found no difference in all-cause mortality between 115 individuals with daily 
and 2,708 individuals without reflux symptoms 18. A cohort study from the UK found that 
patients with GORD (n=7,159) had a 60% increased all-cause mortality within the first year of 
follow-up after inclusion, compared to patients without GORD (n=10,000), but no difference 
was seen for the remaining 4 years of follow-up 19. In our study, reflux was neither 
associated with all-cause mortality after one nor five years of follow-up (data not shown). 
Interpreting the results from the present study and the findings of previous studies indicate 
that reflux does not affect overall all-cause mortality. 
The findings regarding cancer-specific mortality are different from an Iranian population-
based cohort study reporting that participants with severe reflux symptoms (n=172) had a 
48% increase in cancer-specific mortality compared to participants without reflux symptoms 
(n=1,240), while no association was found for oesophageal cancer 20. However, the Iranian 
study could not separate oesophageal adenocarcinoma from squamous cell carcinoma, and 
most oesophageal cancers in Iran are squamous cell carcinomas without any association 
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with reflux 10. Moreover, differences in study design, living conditions and ethnicity, as well 
as chance, may explain the divergent findings.  
Our study confirms the lack of association between reflux and oesophageal squamous cell 
carcinomas as there were no deaths due oesophageal squamous cell carcinoma among the 
participants with severe reflux symptoms, while there were 17 deaths due oesophageal 
squamous cell carcinoma among those without reflux symptoms. Reflux was also, as 
expected, not associated with gastric (non-cardia) cancer-specific mortality (data not 
shown). 
The increased oesophageal adenocarcinoma-related mortality is expected, given the well-
established and strong association between GORD and oesophageal adenocarcinoma 
incidence 10 12. Yet, only 14 of the 4,758 individuals with severe reflux symptoms were 
diagnosed with an oesophageal adenocarcinoma, which emphasizes the fact that the 
absolute risk is low even in individuals with GORD 30. This is, to the best of our knowledge, 
the first study examining the mortality related to head-and-neck and lung cancer, and no 
association was found. 
In conclusion, this prospective and population-based cohort study with a large sample size 
and adjustment for confounding factors indicates that severe reflux symptoms do not entail 
any increased all-cause mortality or overall cancer-specific mortality, although an increase in 
oesophageal adenocarcinoma-specific mortality was found.
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FIGURE LEGENDS 
Figure. Flowchart of inclusion and exclusion of individuals considered for participation in this 
study. *The Nord-Trøndelag Health Study. †Questionnaire for Nonparticipants. 
 
 
 
